Table 2.

Sensitivity analyses for outcomes.

Analysis	Primary analysis HR, 95% CI	Excluding study radiotherapy was not mandatory/stopped prematurely HR, 95% CI	Excluding study available only in abstract form HR, 95% CI	Excluding study HER2 targeted therapy were not available HR, 95% CI
Overall survival	0.97 (0.72–1.29)	0.91 (0.67–1.24)	0.94 (0.63–1.40)	0.96 (0.62–1.48)
Time to locoregional progression	0.36 (0.14–0.95)	0.23 (0.10–0.53)	0.37 (0.07–2.07)	0.56 (0.23–1.37)

Abbreviations: CI- confidence interval, HER2 – human epidermal growth factor receptor 2, HR-hazard ratio.